Literature DB >> 34022396

Advances in targeted therapy for osteosarcoma based on molecular classification.

Yingqian Chen1, Runzhi Liu1, Wei Wang1, Chen Wang1, Ning Zhang2, Xuejing Shao3, Qiaojun He4, Meidan Ying5.   

Abstract

Osteosarcoma, a highly malignant tumor, is characterized by widespread and recurrent chromosomal and genetic abnormalities. In recent years, a number of elaborated sequencing analyses have made it possible to cluster the osteosarcoma based on the identification of candidate driver genes and develop targeted therapy. Here, we reviewed recent next-generation genome sequencing studies and advances in targeted therapies for osteosarcoma based on molecular classification. First, we stratified osteosarcomas into ten molecular subtypes based on genetic changes. And we analyzed potential targeted therapies for osteosarcoma based on the identified molecular subtypes. Finally, the development of targeted therapies for osteosarcoma investigated in clinical trials were further summarized and discussed. Therefore, we indicated the importance of molecular classification on the targeted therapy for osteosarcoma. And the stratification of patients based on the genetic characteristics of osteosarcoma will help to obtain a better therapeutic response to targeted therapies, bringing us closer to the era of personalized medicine.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AT7519 (PubChem CID: 11338033); AZD1152 (PubChem CID: 11497983); Alisertib (PubChem CID: 24771867); Anlotinib (PubChem CID: 25017411); Dinaciclib (PubChem CID: 46926350); Everolimus (PubChem CID: 6442177); HOI-07 (PubChem CID: 72193858); JQ1 (PubChem CID: 46907787); Molecular classification; Nutlin-3a (PubChem CID: 11433190); Osteosarcoma; Palbociclib (PubChem CID: 5330286); Pazopanib (PubChem CID: 10113978); Personalized medicine; RG7112 (PubChem CID: 57406853); Rapamycin (PubChem CID: 5284616); Ridaforolimus (PubChem CID: 11520894); SAR405838 (PubChem CID: 53476877); Sorafenib (PubChem CID: 216239); Sunitinib (PubChem CID: 5329102); THZ1 (PubChem CID: 73602827); Targeted therapy; VX-680 (PubChem CID: 5494449); ZM447439 (PubChem CID: 9914412)

Mesh:

Substances:

Year:  2021        PMID: 34022396     DOI: 10.1016/j.phrs.2021.105684

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  7 in total

1.  Dihydrotanshinone I Enhances Cell Adhesion and Inhibits Cell Migration in Osteosarcoma U-2 OS Cells through CD44 and Chemokine Signaling.

Authors:  Lanyan Fan; Chen Peng; Xiaoping Zhu; Yawen Liang; Tianyi Xu; Peng Xu; Shihua Wu
Journal:  Molecules       Date:  2022-06-09       Impact factor: 4.927

2.  Long Intergenic Noncoding RNA00265 Enhances Cell Viability and Metastasis via Targeting miR-485-5p/USP22 Axis in Osteosarcoma.

Authors:  Ting Chen; Jinxin Liu; He Zhang; Jiatong Li; Guanning Shang
Journal:  Front Oncol       Date:  2022-05-26       Impact factor: 5.738

3.  Multi-omics analysis based on 3D-bioprinted models innovates therapeutic target discovery of osteosarcoma.

Authors:  Yixuan Lin; Yiqi Yang; Kai Yuan; Shengbing Yang; Shuhong Zhang; Hanjun Li; Tingting Tang
Journal:  Bioact Mater       Date:  2022-03-29

4.  A transmembrane protein family gene signature for overall survival prediction in osteosarcoma.

Authors:  Yuehui Du; Xiaohui Zeng; Weiwei Yu; Wei Xie
Journal:  Front Genet       Date:  2022-08-05       Impact factor: 4.772

5.  Optimal Deep Stacked Sparse Autoencoder Based Osteosarcoma Detection and Classification Model.

Authors:  Bahjat Fakieh; Abdullah S Al-Malaise Al-Ghamdi; Mahmoud Ragab
Journal:  Healthcare (Basel)       Date:  2022-06-02

6.  Inhibition of sphingolipid metabolism in osteosarcoma protects against CD151-mediated tumorigenicity.

Authors:  Hongsheng Wang; Xinmeng Jin; Yangfeng Zhang; Zhuoying Wang; Tao Zhang; Jing Xu; Jiakang Shen; Pengfei Zan; Mengxiong Sun; Chongren Wang; Yingqi Hua; Xiaojun Ma; Wei Sun
Journal:  Cell Biosci       Date:  2022-10-08       Impact factor: 9.584

Review 7.  Therapeutic application of hydrogels for bone-related diseases.

Authors:  Xiyu Liu; Shuoshuo Sun; Nan Wang; Ran Kang; Lin Xie; Xin Liu
Journal:  Front Bioeng Biotechnol       Date:  2022-09-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.